Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties

Oncogene volume 34, pages 558–567 (2015)Cite this article

Subjects

Abstract

Diffuse infiltrative invasion is a major cause for the dismal prognosis of glioblastoma multiforme (GBM), but the underlying mechanisms remain incompletely understood. Using human glioma stem cells (GSCs) that recapitulate the invasive propensity of primary GBM, we find that EphA2 critically regulates GBM invasion in vivo. EphA2 was expressed in all seven GSC lines examined, and overexpression of EphA2 enhanced intracranial invasion. The effects required Akt-mediated phosphorylation of EphA2 on serine 897. In vitro the Akt–EphA2 signaling axis is maintained in the absence of ephrin-A ligands and is disrupted upon ligand stimulation. To test whether ephrin-As in tumor microenvironment can regulate GSC invasion, the newly established Efna1;Efna3;Efna4 triple knockout mice (TKO) were used in an ex vivo brain slice invasion assay. We observed significantly increased GSC invasion through the brain slices of TKO mice relative to wild-type (WT) littermates. Mechanistically EphA2 knockdown suppressed stem cell properties of GSCs, causing diminished self-renewal, reduced stem marker expression and decreased tumorigenicity. In a subset of GSCs, the reduced stem cell properties were associated with lower Sox2 expression. Overexpression of EphA2 promoted stem cell properties in a kinase-independent manner and increased Sox2 expression. Disruption of Akt-EphA2 cross-talk attenuated stem cell marker expression and neurosphere formation while having minimal effects on tumorigenesis. Taken together, the results show that EphA2 endows invasiveness of GSCs in vivo in cooperation with Akt and regulates glioma stem cell properties.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683–2710.

    Article  CAS  PubMed  Google Scholar 

  2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459–466.

    Article  CAS  PubMed  Google Scholar 

  3. Chakravarti A, Palanichamy K . Overcoming therapeutic resistance in malignant gliomas: current practices and future directions. Cancer Treat Res 2008; 139: 173–189.

    CAS  PubMed  Google Scholar 

  4. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012; 26: 756–784.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [see comments]. Science 1997; 275: 1943–1947.

    Article  CAS  PubMed  Google Scholar 

  6. TCGA Research Network, Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061–1068.

    Article  Google Scholar 

  7. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807–1812.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F et al. The integrated landscape of driver genomic alterations in glioblastoma 4. Nat Genet 2013; 45: 1141–1149.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A et al. Transforming fusions of FGFR and TACC genes in human glioblastoma 17. Science 2012; 337: 1231–1235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kullander K, Klein R . Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002; 3: 475–486.

    Article  CAS  PubMed  Google Scholar 

  11. Miao H, Wang B . Eph/ephrin signaling in epithelial development and homeostasis. Int J Biochem Cell Biol 2009; 41: 762–770.

    Article  CAS  PubMed  Google Scholar 

  12. Pasquale EB . Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008; 133: 38–52.

    Article  CAS  PubMed  Google Scholar 

  13. Poliakov A, Cotrina M, Wilkinson DG . Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell 2004; 7: 465–480.

    Article  CAS  PubMed  Google Scholar 

  14. Eph Nomenclature Committee, Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee [letter] [In Process Citation]. Cell 1997; 90: 403–404.

    Article  Google Scholar 

  15. Pasquale EB . Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10: 165–180.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Miao H, Wang B . EphA receptor signaling—complexity and emerging themes. Semin Cell Dev Biol 2012; 23: 16–25.

    Article  CAS  PubMed  Google Scholar 

  17. Wykosky J, Gibo DM, Stanton C, Debinski W . EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 2005; 3: 541–551.

    Article  CAS  PubMed  Google Scholar 

  18. Miao H, Li D-Q, Mukherjee A, Guo H, Petty A, Basilion J et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009; 16: 9–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wykosky J, Gibo DM, Debinski W . A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther 2007; 6 (Part 1): 3208–3218.

    Article  CAS  PubMed  Google Scholar 

  20. Wykosky J, Debinski W . The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008; 6: 1795–1806.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Guo H, Miao H, Gerber L, Singh J, Denning MF, Gilliam AC et al. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res 2006; 66: 7050–7058.

    Article  CAS  PubMed  Google Scholar 

  22. Venere M, Fine HA, Dirks PB, Rich JN . Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer’s hierarchy. Glia 2011; 59: 1148–1154.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821–5828.

    CAS  PubMed  Google Scholar 

  24. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396–401.

    Article  CAS  PubMed  Google Scholar 

  25. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA . Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002; 39: 193–206.

    Article  PubMed  Google Scholar 

  26. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De VS et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011–7021.

    Article  CAS  PubMed  Google Scholar 

  27. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100: 15178–15183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756–760.

    Article  CAS  PubMed  Google Scholar 

  29. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Cheng L, Wu Q, Guryanova OA, Huang Z, Huang Q, Rich JN et al. Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun 2011; 406: 643–648.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Garcia JL, Perez-Caro M, Gomez-Moreta JA, Gonzalez F, Ortiz J, Blanco O et al. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas. BMC Cancer 2010; 10: 454.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391–403.

    Article  CAS  PubMed  Google Scholar 

  33. Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008; 13: 69–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009; 4: 568–580.

    Article  CAS  PubMed  Google Scholar 

  35. Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 2001; 3: 527–530.

    Article  CAS  PubMed  Google Scholar 

  36. Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S et al. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Stem Cells 2013; 31: 870–881.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98–110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Wilkinson DG . Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci 2001; 2: 155–164.

    Article  CAS  PubMed  Google Scholar 

  39. Valenzuela DM, Murphy AJ, Frendewey D, Gale NW, Economides AN, Auerbach W et al. High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat Biotechnol 2003; 21: 652–659.

    Article  CAS  PubMed  Google Scholar 

  40. Wegner M . SOX after SOX: SOXession regulates neurogenesis. Genes Dev 2011; 25: 2423–2428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Pevny LH, Nicolis SK . Sox2 roles in neural stem cells. Int J Biochem Cell Biol 2010; 42: 421–424.

    Article  CAS  PubMed  Google Scholar 

  42. Holmberg J, He X, Peredo I, Orrego A, Hesselager G, Ericsson C et al. Activation of neural and pluripotent stem cell signatures correlates with increased malignancy in human glioma. PLoS One 2011; 6: e18454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D . SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genom Proteom 2011; 8: 139–147.

    CAS  Google Scholar 

  44. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009; 27: 40–48.

    Article  CAS  PubMed  Google Scholar 

  45. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704–715.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Chaffer CL, Weinberg RA . A perspective on cancer cell metastasis. Science 2011; 331: 1559–1564.

    Article  CAS  PubMed  Google Scholar 

  47. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69–82.

    Article  CAS  PubMed  Google Scholar 

  48. Miao H, Burnett E, Kinch M, Simon E, Wang B . Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2000; 2: 62–69.

    Article  CAS  PubMed  Google Scholar 

  49. Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W . EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Mol Cell Biol 2012; 32: 3253–3264.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, Debinski W . Soluble monomeric ephrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 2008; 27: 7260–7273.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Molina JR, Hayashi Y, Stephens C, Georgescu MM . Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia 2010; 12: 453–463.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Petty A, Myshkin E, Qin H, Guo H, Miao H, Tochtrop GP et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One 2012; 7: e42120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 2012; 22: 765–780.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Johnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, Pounds SB et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 2010; 466: 632–636.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS et al. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 2013; 23: 238–248.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from National Institute of Health CA152371 (HM and BW), CA155676 (BW) and by awards to BW from FAMRI Foundation (072216_CIA) and Prayers From Maria Foundation. This research was also supported by the Case Comprehensive Cancer Center (P30 CA43703).

Author information

Authors and Affiliations

  1. Rammelkamp Center for Research, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA

    H Miao, H Guo, J Qian, A Petty, J Kaspar & B Wang

  2. Department of Pharmacology and Oncology, Case Western Reserve University School of Medicine, Cleveland, OH, USA

    H Miao, H Guo, J Qian, A Petty, J Kaspar & B Wang

  3. VelociGene Division, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA

    N W Gale, A J Murphy, D M Valenzuela & G Yancopoulos

  4. Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

    D Hambardzumyan, J D Lathia, J N Rich & J Lee

  5. Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, OH, USA

    D Hambardzumyan, J D Lathia, J N Rich, J Lee & B Wang

Authors
  1. H Miao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N W Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Petty
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Kaspar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A J Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D M Valenzuela
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Yancopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Hambardzumyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J D Lathia
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J N Rich
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. B Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Wang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miao, H., Gale, N., Guo, H. et al. EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene 34, 558–567 (2015). https://doi.org/10.1038/onc.2013.590

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2013.590

Keywords

This article is cited by

Search

Advanced search

Quick links